Pharmacopeia and Organon
Pharmacopeia and Organon have signed a new 5-year collab- oration. Organon will provide Pharmacopeia with numerous assays, which will be used to identify and optimise drug candidates for multiple targets that meet specific criteria. Pharmacopeia will then license these optimised drug candidates to Organon.
The companies have an established successful relationship and will continue to collaborate on the optimisation of Pharmacopeia's small molecule antagonists of the IL-8 CXCR2 receptor to treat inflammatory diseases.